



# Enzymes III

## *Regulation*

Summer semester, 2023

# Mechanisms of regulation




- Non-specific regulation (temperature, pH, diffusion, and expression)
  - Localization (compartmentalization and complexing of enzymes)
  - Expression of isoenzymes
- Regulation of enzymatic activity
  - Inhibitors
  - Conformational changes
    - Modulators
    - Reversible covalent modification
    - Irreversible covalent modification
    - Allostery

# Temperature




- Reaction rates increase with temperature due to increased kinetic energy of the molecules resulting in more collisions between enzymes and substrates.
- However, high temperatures lead to protein denaturation.
- Each enzyme has an optimal temperature.
- For thermophilic bacteria, the optimal temperature is as high as 65°C.





- pH alters the protonation state of the substrate and/or the enzyme and, hence, their binding.
- The effect of pH is enzyme-dependent.






# Regulation of enzyme amount



- Three mechanisms:
  - Enzyme synthesis at the gene level
  - Enzyme degradation by proteases
  - Synthesis of isozymes
- They are comparatively slow mechanisms for regulating enzyme concentration (hours-weeks).





| Enzyme                | Half-life (days) |
|-----------------------|------------------|
| Catalase              | 1.4 days         |
| Glucokinase           | 1.2 days         |
| Lactate dehydrogenase |                  |
| LDH1 (heart)          | 1.6              |
| LDH5 (liver)          | 16               |
| LDH5 (muscle)         | 31               |

# Compartmentalization






- Compartmentalization reduces the area of diffusion of both enzyme and substrate increasing the probability that they collide.
  - Example 1: lysosomal enzymes
  - Example 2: fatty acid metabolism
  - Synthesis occurs in cytosol, whereas break-down is mitochondrial.



# Enzyme complexing



- Formation of a complex of multiple enzymes also reduces diffusion.
- Example: Pyruvate dehydrogenase (mitochondria) is composed of 3 enzymes: decarboxylation, oxidation, & transfer of the acyl group to CoA.







# Isoenzymes (isozymes)




- Isoenzymes are enzymes that can act on the same substrate(s) producing the same product(s).
- They are produced by different genes that vary only slightly.
- Often, various isozymes are present in different tissues of the body.
- They can be regulated differently .
- They can have different catalytic activities.







# Aerobic vs. anaerobic metabolism





# Lactate dehydrogenases (LDH)



- LDH is a tetrameric enzyme composed of a combination of one or two protein subunits: H (heart) and M (skeletal muscle).
- These subunits combine in various ways leading to 5 distinct isozymes leading to 5 distinct isozymes (LDH1-5) with different combinations of the M and H subunits.
- The all H isozyme is characteristic of that from heart tissue, and the all M isozyme is typically found in skeletal muscle and liver.






- Although the five isoforms catalyze the same reaction, they differ in their primary structure (slightly), kinetic properties, tissue distribution, affinity to the substrate, regulation, and isoelectric point.
- The M subunit has a net charge of (-6) and higher affinity towards pyruvate, thus converting pyruvate to lactate (and NADH to NAD+).
- The H subunit has a net charge of (+1) and a higher affinity towards lactate, resulting in a preferential conversion of lactate to pyruvate (and NAD+ to NADH).



# Logic behind tissue distribution




| Isoenzyme | Structure                        | Present in             | Elevated in                        |
|-----------|----------------------------------|------------------------|------------------------------------|
| LDH1      | (H <sub>4</sub> )                | Myocardium             | myocardial infarction              |
| LDH2      | (H <sub>3</sub> M <sub>1</sub> ) | RBC                    |                                    |
| LDH3      | (H <sub>2</sub> M <sub>2</sub> ) | Lungs                  |                                    |
| LDH4      | (H <sub>1</sub> M <sub>3</sub> ) | Kidney                 |                                    |
| LDH5      | (M <sub>4</sub> )                | Skeletal muscle, Liver | Skeletal muscle and liver diseases |

# Function of isozymes



- Muscles can function anaerobically, but heart tissues cannot.
- Whereas the all-M isozyme (M4) functions anaerobically and catalyzes the reduction of pyruvate into lactate, the all-H enzyme (H4) functions aerobically and catalyzes the reverse reaction.



# Regulation of LDH




- H4 LDH has a low  $K_m$  for lactate, high  $K_m$  for pyruvate, and is inhibited by high levels of pyruvate.
  - The H4 isoenzyme favors (lactate to pyruvate).
- The M4 LDH enzyme has a high  $K_m$  for pyruvate and is not inhibited by pyruvate.
  - M4 LDH is always active even at high levels of pyruvate ensuring that pyruvate is always funneled to anaerobic metabolism.



# Hexokinase vs glucokinase




- Hexokinase and glucokinase (hexokinase IV) are allosteric isozymes that catalyze:  
**Glucose → Glucose-6-Phosphate**
- Glucokinase is a liver (and pancreatic) enzyme, whereas hexokinase is ہی RBC (and skeletal muscle) enzyme.
  - The purpose of liver glucose is to balance glucose level in the blood.
  - The purpose of RBC glucose is to produce energy.



# Biological significance





- Note: once glucose is phosphorylated, it cannot cross plasma membrane out of cells.
  - Liver: low efficiency enzyme to provide glucose to other organs.
  - RBC and skeletal muscles: high efficiency enzyme to trap glucose.



# Regulation of hexokinase and glucokinase



- Note  $V_{max}$  and  $K_M$  values (low - 0.1 mM for hexokinase and (high - 10 mM for glucokinase)
- Regulation
  - Hexokinase is inhibited by glucose-6-phosphate, but glucokinase is not.
  - Glucokinase is activated by insulin and inhibited by glucagon.
- Significance:
  - At fasting state, glucose is not stored.
  - At well-fed state, RBCs and skeletal muscles do not consume all glucose in blood and liver can convert excess glucose in glycogen for storage.





# Regulation of enzymatic activity

# Inhibitors

# Enzyme inhibitors







- Enzyme inhibition can be either reversible or irreversible.
  - Reversible inhibitors rapidly dissociate from enzymes (e.g. non-covalent binding).
    - Competitive, noncompetitive, or uncompetitive inhibition.
  - An irreversible inhibitor is tightly bound (e.g. covalently) to the enzyme.
    - Lower concentration of active enzyme.



# Competitive inhibition








- Competitive inhibitors compete with the substrate for the active site.
  - Increasing substrate can overcome inhibition.
- Same  $V_{max}$ , but higher  $K_M$



# Noncompetitive inhibition




- Noncompetitive inhibitors bind E or ES complex at a site other than the catalytic site.
- Substrate can bind to the enzyme-inhibitor complex, but ESI cannot form a product.
- Lower  $V_{max}$ , but same  $K_M$






# Uncompetitive inhibition



- Uncompetitive inhibitors bind to the enzyme-substrate complex only reducing both  $V_{max}$  and  $K_M$ .



UNCOMPETITIVE



# Mechanism-based inhibitors



## Irreversible inhibitors


- Mechanism-based inhibitors mimic or participate in an intermediate step of the catalytic reaction.
- They include:
  - Covalent inhibitors
  - Transition state analogs
  - Heavy metals
- Irreversible inhibitors decrease the concentration of active enzyme.




# Covalent inhibitors

- They form covalent or extremely tight bonds with active site amino acids.
  - **Example: diisopropyl fluorophosphate (DFP) is a organophosphate**
    - The nerve gas sarin
    - The insecticides malathion & parathion.
    - DFP inhibits acetylcholinesterase preventing the degradation of the neurotransmitter acetylcholine.


**DFP also inhibits other enzymes that use serine (ex. serine proteases), but not lethal.**



Malathion




Parathion




Sarin

## A. Normal reaction of acetylcholinesterase




## B. Reaction with organophosphorus inhibitors



# Aspirin



- Aspirin (acetylsalicylic acid) acetylates an active site serine of cyclooxygenase.
- Aspirin resembles a portion of the prostaglandin precursor that is a physiologic substrate for the enzyme.



# Substrate and transition-State analogs





## Suicide inhibitors

- They bind more tightly than substrates.
- Drugs cannot be designed that precisely mimic the transition state! (highly unstable structure).



# Methotrexate



- Methotrexate is a synthetic inhibitor used to treat cancer.
- It is a structural analog of folate, a substrate for the enzyme dihydrofolate reductase, and a coenzyme for thymidylate kinase, both of which are responsible for the synthesis of nucleotides.
- It binds to dihydrofolate reductase 1000-fold more tightly than the natural substrate and inhibits nucleotide base synthesis.



# Penicillin




- The cell wall is the outer covering of the bacteria-containing peptidoglycan layer which is made up of peptides that are cross-linked by glycopeptidyl transpeptidase.
- The amide bond in the  $\beta$ -lactam ring of penicillin looks like the natural transition-state complex.
  - Penicillin is an irreversible, transition-state analog inhibitor of the enzyme.
- The active site serine attacks the highly strained  $\beta$ -lactam ring.



# Heavy Metals



- Mercury (Hg), lead (Pb), aluminum (Al), or iron (Fe) result in tight binding to a functional group in an enzyme .
  - **Nonspecific inhibition at high doses.**
- Mercury binds to reactive sulfhydryl groups away from the active site and affect the binding of substrates.
  - **Unknown enzymes are inhibited in mercury toxicity.**
- Lead replaces the normal functional metal in an enzyme such as calcium, iron, or zinc by an irreversible mechanism.
  - Its developmental & neurologic toxicity may be caused by its ability to replace  $\text{Ca}^{+2}$  in several regulatory proteins that are important in the central nervous system and other tissues.









# Regulation through conformational changes


# The different fates of glucose



# Metabolism of glycogen



# Regulation by phosphorylation








# PKA-structure and regulation



- When inactive, protein kinase A (PKA), a serine/threonine kinase, consists of four subunits (R<sub>2</sub>C<sub>2</sub>).
  - Two regulatory (R) subunits with high affinity for cAMP,
  - Two catalytic (C) subunits
- PKA phosphorylates several enzymes that regulate different metabolic pathways.
  - Example: glycogen phosphorylase kinase





# The many targets of PKA



# cAMP and protein kinase A (PKA)



- Small-molecule modulators can have dramatic effects on enzymes.
- For example, cAMP, which is structurally modified AMP, can activate protein kinase A (PKA).
- The binding of two molecules of cAMP to each regulatory subunit leads to the dissociation of R<sub>2</sub>C<sub>2</sub> into an R<sub>2</sub> subunit and two active C subunits.






# Reversible covalent modification




# Advantage




- Rapid and transient
- A most common mechanism is enzyme phosphorylation (the covalent addition of a phosphate group to one of its amino acid side chains).
  - Usually serine, threonine, and tyrosine



# Enzymes catalyzing (de)phosphorylation



- ATP mostly is the phosphoryl donor in these reactions, which are catalyzed by protein kinases.
- The removal of phosphoryl groups (dephosphorylation) by hydrolysis is catalyzed by protein phosphatases.
- Note: dephosphorylation is not the reversal of phosphorylation.
- The addition or removal of a phosphate group to an enzyme may activate or inactivate these enzymes.



# Why is phosphorylation effective?



- Formation or removal of new electrostatic interactions and/or hydrogen bonds altering substrate binding and catalytic activity.
- It can happen in less than a second or over a span of hours.
- Phosphorylation often causes highly amplified effects.






# Others



- Adenylation (addition of adenylyl group). AMP is transferred to Tyr residues through phosphodiester linkage.
- The addition of bulky AMP inhibits cytosolic enzymes.
- Uridylation (addition of uridylyl group).
- ADP-ribosylation (addition of adenosine diphosphate ribosyl group) inactivates enzymes.
- Methylation of carboxylate side chains masking negative charges.
- Acetylation (from acetyl Co) to lysine residues masking positive charges.


## Covalent modification (target residues)

### Adenylation (Tyr)




## Covalent modification (target residues)

### Uridylation (Tyr)




## Covalent modification (target residues)

### ADP-ribosylation (Arg, Gln, Cys, diphthamide—a modified His)




## Covalent modification (target residues)

### Methylation (Glu)






# Phosphorylation cascade




# Example: Glycogen phosphorylase



- GP catalyzes the removal of glucose molecules from glycogen.
- The phosphorylated Ser residue is remote from the active site.
- The enzyme exists in four forms:
  - T (inactive) or R (active) states and
  - Phosphorylated (a) or dephosphorylated (b)




- *When phosphorylated, it is known as phosphorylase a.*
- *When dephosphorylated, it is known as phosphorylase b.*




# The two forms of each form



- Both phosphorylase b and phosphorylase a exist in equilibrium between an active R state and a less-active T state.
- Phosphorylase b is usually inactive because the equilibrium favors the T state.
- Phosphorylase a is usually active because the equilibrium favors the R state.





The transition of phosphorylase b between the T and the R state is controlled by the energy charge (ATP and AMP) of the muscle cell and the availability of glucose-6-phosphate.




# What do ATP and AMP do?




- Muscle phosphorylase *b* is active only in the presence of high concentrations of AMP, which binds to a nucleotide-binding site and stabilizes the conformation of phosphorylase *b* in the R state.
- ATP acts as a negative allosteric effector by competing with AMP and so favors the T state.

**Glucose 6-phosphate also favors the T state of phosphorylase *b*, an example of feedback inhibition.**



# Or phosphorylate glycogen of phosphorylase b




# Large and small regulatory modulators



## Trimeric large G proteins

- Trimeric G proteins: a family of membrane-bound proteins causing changes inside the cell. They communicate signals from hormones, neurotransmitters, and other signaling factors through G protein-coupled receptors (GPCRs)

- When they bind GTP, they are 'on', and, when they bind GDP, they are 'off'.
- The  $\alpha$  subunit binds to effectors stimulating or inhibiting them.





# Large and small regulatory modulators




## Small monomeric G proteins

- When GTP is bound, the conformation of the G protein allows it to bind target proteins, which are then activated or inhibited.
- The G protein hydrolyzes a phosphate from GTP to form GDP, which changes the G protein conformation and causes it to dissociate from the target protein.
- GDP is exchanged for GTP, which reactivates the G protein.

**The activity of many monomeric G proteins is regulated by**

- 1. GAPs [GTPase-activating proteins]**
- 2. GEFs [guanine nucleotide exchange factors]**
- 3. GDIs [GDP dissociation inhibitors]**







# Irreversible covalent modification (Proteolytic activation)

# Zymogens



- Zymogens or proenzymes are inactive precursors of enzymes.
- Activation is done by irreversibly removing part of the enzyme (usually known as the pro region present at the N-terminus).
- Examples: digestive enzymes such as chymotrypsin, trypsin, and pepsin that get activated when food is ingested.
  - **Trypsinogen (zymogen) is activated via removal of the first six amino acids at the N-terminus.**



# Regulation: conformational changes



- These regulatory mechanisms include
  - **Allostery**
  - **Covalent modulation**
  - **Protein-protein interactions between regulatory & catalytic subunits or between two proteins;**
  - **Proteolytic cleavage**
- Rapidly change from inactive to fully active enzyme.





# Allosteric regulation



# Allosteric enzymes and their modifiers




- Allosteric enzymes are multi-subunit proteins;
  - One subunit contains the active site (catalytic subunit) and another containing the regulatory site (regulatory subunit).
  - Multiple active sites can exist on multiple subunits.
- The binding of regulatory molecules triggers conformational changes in the active site via modifying non-covalent interactions.
- Allosteric enzymes bind modifiers at the allosteric site, a site that is physically separate from the catalytic site.
  - A negative allosteric modifier (inhibitor) causes the enzyme to have less activity.
  - A positive allosteric modifier (activator) causes the enzyme to be more active.



# More on modifiers



- When the modifier is a molecule other than the substrate, then it is known as heterotropic.
- If the modifier is same as the substrate, then it called homotropic.
  - The binding of the substrate causes the enzyme to become more active and binds to a second substrate at a different active site with more ease.
  - This is called "positive cooperativity".
  - T to R conformation
  - There is also negative cooperativity.




# Types of allosteric enzymes




- The Michaelis-Menten model cannot explain the kinetic properties of allosteric enzymes.
- $K_{0.5}$  is used instead of  $K_M$ .

## V system



**Same  $K_{0.5}$ , Different  $V_{max}$ .**

## K system



**Different  $K_{0.5}$ , same  $V_{max}$ .**

**Note near-hyperbolic plot with activators**



# Allosteric enzymes and metabolism







- Allosteric inhibitors usually have a much stronger effect on enzyme velocity than competitive and noncompetitive inhibitors.
- Allosteric enzymes are not limited to regulation through inhibition whereby allosteric effectors may function as activators.
- The allosteric effector needs not bear any resemblance to substrate or product of the enzyme.
- The effect of an allosteric effector is rapid occurring as soon as its concentration changes in the cell.
  - **Feedback regulation of metabolic pathways by end products or by signal molecules that coordinate multiple pathways.**



# Aspartate transcarbamoylase





- Aspartate transcarbamoylase (ATCase) catalyzes the first step in the synthesis of pyrimidine nucleotides.
- ATCase consists of 12 polypeptide chains: six catalytic subunits (two trimers) and six regulatory subunits (three dimers).
- It exists in two forms: T state (less active) and R state (more active).



# Aspartate transcarbamoylase-regulation



- ATCase is inhibited by CTP, the end-product
  - inducing a major rearrangement of subunit positions
  - stabilizing the T state of the enzyme.
  - decreasing binding affinity for Asp (substrate) at active sites on catalytic subunits
  - increasing  $K_{0.5}$  (K system)
    - Note: a non-competitive inhibitor changes  $K_{0.5}$
    - On the other hand, ATP, a purine, heterotypically activates the enzyme in order to balance the rate of synthesis of purines and pyrimidines in cells.




# Modes of metabolic regulation

# Feedback inhibition



- Feedback inhibition or negative feedback regulation: an enzyme present early in a biochemical pathway is inhibited by a late product of pathway.



**AT REST**  
**(glycolysis inhibited)**

**Glucose**



**Hexokinase**

**Glycogen**



**Glucose 6-phosphate**





***AKA, product inhibition***  
**Negative feedback**



# Feedback activation




- Positive feedback regulation: a product stimulates the activity of an enzyme.





# Feed-forward activation



- Feed-forward regulation: a substrate produced early in a pathway activates an enzyme downstream of the same pathway.




- Glycolysis
- Poisoning





# A committed step



- A committed step in a metabolic pathway is the first irreversible reaction that is unique to a pathway and that, once occurs, leads to the formation of the final substrate with no point of return.
- Committed steps are exergonic reaction.
- For example, the committed step for making product E is ( $B \rightarrow C$ ), not ( $A \rightarrow B$ ).



# PFK, not HK/GK, is the committed step





# Rate-limiting reactions



- Rate-limiting reactions slow down rate of reactions because:
  - requirement for high amount of energy
  - strict regulation of enzymes
  - high  $K_m$  values of enzyme towards its substrate
- These reactions are also usually, but not necessarily, committed steps.





Figure 12-3  
Molecular Cell Biology, Sixth Edition  
© 2008 W. H. Freeman and Company

# Enzymes in disease diagnosis




- The presence of enzymes in serum indicates that tissue or cellular damage.
- The measurement enzyme amount in serum is of diagnostic significance.
- Examples:
  - The amino transferases: alanine transaminase, ALT and aspartate aminotransferase, AST
  - Lactate dehydrogenase, LDH
  - Creatine kinase, CK (also called creatine phosphokinase, CPK)

# AST and ALT




- The typical liver enzymes measured are AST and ALT.
- ALT is predominantly in hepatocytes.
- The ratio of ALT/AST is diagnostic.
  - Liver disease/damage (not of viral origin)  $< 1$ .
  - Viral hepatitis  $> 1$ .







# Protein profile in myocardial infarction





- A comparison of serum levels of LDH-1/LDH-2 ratio is diagnostic for myocardial infarction (heart attacks).
- Normally, this ratio is less than 1.
- Following an acute myocardial infarct, the LDH ratio will be more than 1.






- CPK is found primarily in heart and skeletal muscle as well as the brain.
- Three tissue-specific isozymes of CPK:
  - **CPK3 (CPK-MM)**
  - **CPK2 (CPK-MB)**
  - **CPK1 (CPK-BB)**

| Serum                           | Skeletal Muscle               | Cardiac Muscle                          | Brain                   |
|---------------------------------|-------------------------------|-----------------------------------------|-------------------------|
| 0 trace BB<br><6% MB<br>>94% MM | 0 trace BB<br>1% MB<br>99% MM | 0% BB<br><b>20% MB</b><br><b>80% MM</b> | 97% BB<br>3% MB<br>0%MM |

# CPK and myocardial infarction



- A significant amount of CPK-MB is released after MI leading to increased CPK-MB/total CPK ratio (diagnostic of an acute infarction).
  - **An increase of total CPK in itself may not.**
- CPK-MB disappears in 1-3 days, so another elevation is indicative of another event (reinfarction).






# Example



## Correspondence Between CPK and LDH Isoenzyme Patterns



# Interpretation



- Sample #3 represents results for standard proteins.
- Sample #8 results are from a normal specimen.
- Sample# 1 MI patient. The specimen was collected at a time when the activity of both LDH and CK were elevated. Note the LDH flip and the high relative activity of the MB isoenzyme.
- Sample# 2 MI patient who experienced chest pain only several hours previously. Total CK is significantly elevated.
- Sample# 6 MI patient (the 1st day post MI); CK level is elevated with a high relative MB isoenzyme activity and the LDH flip is evident.
- Sample# 5 MI patient (2 days post MI) is like sample #6, but lower CK levels.
- Sample# 7 MI patient with passive liver congestion or the patient was involved in an accident as a consequence of the MI, and suffered a crushing muscle injury.
- Sample# 4 a patient with liver disease.



- Troponin levels rise within four to six hours after the beginning of chest pain or heart damage and stay elevated for at least one week.
- This long elevation allows detection of a myocardial infarction that occurred days earlier but prevents detection of a second infarction if it occurred only days after the first.